TITLE

All-oral hep. C combos threaten interferon

AUTHOR(S)
Iskowitz, Marc
PUB. DATE
June 2012
SOURCE
Medical Marketing & Media;Jun2012, Vol. 47 Issue 6, p16
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the development of an oral drug for treating hepatitis C virus. According to a clinical trial, an all-oral therapy joining daclatasvir from BMS and Gilead Sciences Inc.'s GS-7977 has suppressed the virus in more than 95 percent of patients across a broad spectrum of genotypes. It states that the two drugs has reached a 100 percent sustained virologic response (SVR) in patients not previously treated with interferon.
ACCESSION #
76378534

 

Related Articles

  • Vantage Point. GLOR, JEFF // Medical Marketing & Media;Jan2013, Vol. 48 Issue 1, p31 

    The article provides information on the pharmaceutical industry. It discusses the 2012 approval of Vertex Incivek and Merck Victrelis. It says that the next agents from Gilead, Abbott, BMS, Janssen and others will offer short therapy. It also mentions a success story that happened due to a great...

  • FDA approvals usher in the post-interferon era in HCV. Sheridan, Cormac // Nature Biotechnology;Jan2014, Vol. 32 Issue 1, p3 

    The article focuses on the approval of the U.S. Food and Drug Administration (FDA) to the Sovaldi drug from Gilead Sciences Inc. and to the Olysio drug from Janssen Pharmaceutical which usher the new era of hepatitis C virus (HCV) therapy. Topics discussed include the goal of eliminating...

  • GILEAD SCIENCES, INC.  // Contract Pharma;Jul/Aug2012, Vol. 14 Issue 6, p94 

    The article offers information on various drugs developed by Gilead Sciences Inc. based in Foster City, California. It mentions the Eviplera/Complera, an approved drug for HIV-1 infection. It states that drugs such as Elvitegravi and Cobicistat for HIV/AIDS and GS-7977 for hepatitis C are in...

  • Hep-C: Profit-Tier Pricing. ALLEN, TERRY J. // In These Times;Nov2014, Vol. 38 Issue 11, p16 

    The article focuses on Gilead Sciences Inc., which faced a fiscal challenge with its new drug, Sovaldi. It is mentioned that the drug reportedly cures up to 90 percent of people with hepatitis C, a viral infection and represents a finite cure due to which Gilead set the price at an astounding...

  • Gilead Adds To Biotech Woes. Investor's Business Daily // Investors Business Daily;3/31/2014, pA01 

    6

  • Gilead Sciences to Acquire Pharmasset Inc. for $11 Bln.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p93 

    The article reports on the acquisition of Pharmasset Inc. by Gilead Sciences Inc. for 11 billion dollars in the U.S. Clinical trials for the uracil nucleotide PSI-7977 of Pharmasset are highlighted which will be indicated for the treatment of chronic hepatitis C. According to John C. Martin,...

  • Infectious Diseases. Pines, Noah // Medical Marketing & Media;Jun2013, Vol. 48 Issue 6, p42 

    The article focuses on the advancements on hepatitis C virus (HCV) treatment and the challenges to be faced despite such advancements. It says that upgrades in HCV therapy shows progress on efficacy, tolerability, and convenience. It mentions sofosbuvir (GS-7977) hepatitis C drug from Gilead...

  • Why Gilead Is Falling On Drugs For Developing Nations. ELAINE LOW // Investors Business Daily;9/5/2014, p00 

    Shares of

  • New Expensive Treatments for Hepatitis C Infection. Brennan, Troyen; Shrank, William // JAMA: Journal of the American Medical Association;8/13/2014, Vol. 312 Issue 6, p593 

    The article discusses changes in the treatment options for hepatitis C virus (HCV) infection. Topics discussed include an overview of past treatment courses involving the drugs pegylated interferon and ribavirin, the use of polymerase inhibitors as the standard course of treatment in 2014, and...

Share

Other Topics